Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Halychpharm A pharmaceutical manufacturer of finished medicines and plant-derived phytochemical substances.	Ukraine	GFARM
HANALL BIOPHARMA CO.,LTD Develops innovative medicines for chronic diseases through antibody and small molecule research.	South Korea	009420
Hana Pharm. Co., Ltd. Pharmaceutical firm specializing in anesthetics and narcotic analgesics for global markets.	South Korea	293480
Hanmi Pharm. Co., Ltd. Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.	South Korea	128940
Hansa Biopharma Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.	Sweden	HNSA
Harmony Biosciences Holdings, Inc. Develops innovative therapies for rare neurological diseases, focusing on conditions like narcolepsy.	United States of America	HRMY
HARROW, INC. Develops branded ophthalmic therapies and custom compounded solutions for North American eyecare.	United States of America	HROW
HCW Biologics Inc. Developing novel immunotherapies to treat aging-related chronic inflammation.	United States of America	HCWB
HEALIOS K.K. Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.	Japan	4593
Ｈｅａｒｔｓｅｅｄ株式会社 Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.	Japan	219A